Workflow
GMAB vs. TECH: Which Stock Is the Better Value Option?
Bio-TechneBio-Techne(US:TECH) ZACKSยท2024-07-08 17:07

Core Viewpoint - Genmab A/S Sponsored ADR (GMAB) is currently viewed as a better value opportunity compared to Techne (TECH) based on various valuation metrics and earnings outlook [1][6]. Valuation Metrics - GMAB has a P/B ratio of 3.57, while TECH has a higher P/B of 5.57, indicating GMAB is more undervalued relative to its book value [3]. - The forward P/E ratio for GMAB is 23.03, significantly lower than TECH's forward P/E of 34.71, suggesting GMAB is more attractively priced [5]. - GMAB's PEG ratio stands at 0.93, which is favorable compared to TECH's PEG ratio of 6.51, indicating better expected earnings growth relative to its price [5]. Earnings Outlook - GMAB holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while TECH has a Zacks Rank of 3 (Hold), suggesting a less favorable earnings forecast [4]. - The positive earnings estimate revisions for GMAB further support its superior position in terms of earnings outlook compared to TECH [4][6]. Value Grades - GMAB has received a Value grade of B, reflecting its strong valuation metrics, while TECH has a Value grade of D, indicating weaker valuation characteristics [9].